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Abstract We investigated the e¡ect of testosterone (T) on tu-
mor necrosis factor-K (TNF-K)-induced expression of vascular
cell adhesion molecule-1 (VCAM-1) in human aortic endothelial
cells. Incubation of these cells with T resulted in a dose-depen-
dent reduction in the expression, with this reduction completely
abolished by a selective androgen receptor blocker. Electropho-
retic mobility shift assay demonstrated that T inhibited TNF-K-
induced activation of the transcriptional nuclear factor-UB,
which is critical for the inducible expression of VCAM-1, prob-
ably through the suppression of the nuclear translocation. Our
results may suggest an inhibitory e¡ect of T on atherogenesis,
providing a novel insight into the consideration of the patho-
genesis of atherosclerosis.
+ 2002 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
The issue of testosterone (T) replacement in older men is
just beginning to be addressed. There is agreement that
T levels decline progressively with advancing age, and that
many of the physiological changes that occur with aging are
similar to those associated with androgen de¢ciency in young
men. Some studies have reported that T administration to
older men with low or low normal T levels improves various
physiological indices [1,2]. However, it is premature to make a
general recommendation about T replacement in these men,
because the risks of long-term T administration, particularly
the risk of cardiovascular disease, are unknown.
T, the main circulating androgen, can be converted into 5K-
dihydrotestosterone (5KDHT) by the action of the enzyme 5K-
reductase (5K-R) in the target tissues such as the prostate
before binding to androgen receptor (AR). T is also the sub-
strate for the enzyme aromatase which irreversibly transforms
the androgen into estrogen (estradiol). There are two 5K-R
isozymes in humans. The type 1 5K-R (5K-R1) displays a
low a⁄nity for T, while the type 2 isozyme (5K-R2) shows a
high a⁄nity for the androgen and is generally considered the
main isoform in the target tissues [3^5].
One of the initial events in atherogenesis is the activation of
endothelial cells. The activation by atherogenic stimuli such as
cytokines and oxidative free radicals results in the enhanced
expression of cell surface adhesion molecules such as vascular
cell adhesion molecule-1 (VCAM-1), intercellular adhesion
molecule-1 and E-selectin, which in turn facilitates the attach-
ment of blood leukocytes to endothelial surfaces [6,7]. Recent
evidence indicates that the promoter region of genes for ad-
hesion molecules contains nuclear factor-UB (NF-UB), a tran-
scriptional activator protein, binding sites which are essential
for the expression of these genes [8]. Tumor necrosis factor-K
(TNF-K), the principal atherogenic cytokine, mediates its cel-
lular responses via activation of the NF-UB [9].
There is a widespread perception that T supplementation
increases the risk of atherosclerotic heart disease. However,
the available data do not support this premise, and the mech-
anisms by which T may promote atherogenesis have not been
determined [10]. Since leukocyte recruitment into the vascular
wall following adhesion to endothelial cells is a crucial step in
the pathogenesis of atherosclerosis, it appeared promising to
investigate whether T, a presumed atherogenic substance,
might modulate endothelial adhesion molecule expression. In
the present study, we examined the e¡ect of T on TNF-K-
induced VCAM-1 expression and also on the activation of
NF-UB in cultured human aortic endothelial cells (HAEC).
2. Materials and methods
2.1. Cell culture
HAEC were cultured according to the supplier’s instruction (Clo-
netics, Walkersville, MD, USA). Cells at passage 4^6 were used for
the experiments.
2.2. Reverse transcription-polymerase chain reaction (RT-PCR)
RT-PCR assay was performed as described previously [11]. AR
primers were 5P-CCAGGAGACCTGCCTGATCTG-3P and 5P-
CCTCCTGTAGTTTCAGATTACC-3P [12]. 5K-R1 primers were 5P-
AGCAGATACTTGAGCCA-3P and 5P-CCAAAATAGTTGGCTG-
C-3P [3]. 5K-R2 primers were 5P-ACATTACTTCCACAGGACATT-
T-3P and 5P-AGGAAATTGGCTCCAGA-3P [13]. P450 aromatase
primers were 5P-GAATATTGGAAGGATGCACAGACT-3P and 5P-
GGGTAAAGATCATTTCCAGCATGT-3P [14].
2.3. Assay of 5K-R activity
5K-R activity was measured by a radiometric conversion assay as
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previously described [15]. In brief, con£uent HAEC were incubated in
phenol red-free and serum-free medium containing 100 nM [1,2,6,7-
3H]T (Amersham Pharmacia Biotech, Buckinghamshire, UK) for 2 h
at 37‡C, after which steroids were extracted with ethyl ether and were
resolved by thin layer chromatography. Blanks were run for each
assay, using culture dishes without cells. Radioactivities correspond-
ing to T and 5KDHT were determined. 5K-R activity was calculated
as counts per minute (cpm) for 5KDHT/(cpm for T+cpm for
5KDHT)U100.
2.4. Whole cell binding assay
AR binding assay was performed as previously described [15]. In
brief, con£uent HAEC were incubated in phenol red-free and serum-
free medium with 2% bovine serum albumin containing 0^16 nM
[1,2,6,7-3H]T or [1,2,4,5,6,7-3H]5KDHT (Amersham Pharmacia Bio-
tech) for 2 h at 37‡C in the absence or presence of 500 nM of un-
labeled steroids to determine the total and non-speci¢c binding, re-
spectively. At the end of the incubation, the cells were washed four
times with serum-free medium, solubilized in 0.1 N NaOH. The radio-
activity of the content was counted with a liquid scintillation counter.
The remaining content was used for the determination of protein by a
Bio-Rad protein assay kit (Bio-Rad, Hercules, CA, USA).
2.5. Northern blot analysis
Con£uent cells were incubated with test compounds or vehicle
(0.1% ethanol) for 24 h in phenol red-free and serum-free medium,
and thereafter were stimulated with 20 ng/ml TNF-K (Sigma, St.
Louis, MO, USA) for 4 h. Northern blot analysis was performed as
previously described [16] with the use of total RNAs (20 Wg) isolated
from HAEC and human VCAM-1 cDNAs. The cDNA probe was
originally obtained by RT-PCR with HAEC total RNA. The sequence
was veri¢ed by the dideoxy chain termination method.
2.6. Nuclear extraction and electrophoretic mobility shift assay
(EMSA)
HAEC were treated with test compounds and/or TNF-K, as de-
scribed above. The nuclear extracts were prepared by the method of
Schreiber et al. [17]. EMSA for NF-UB was performed as described
[18]. The sequence of double-stranded oligonucleotide used to deter-
mine the DNA binding abilities of NF-UB was derived from the hu-
man VCAM-1 gene promoter [19]. The NF-UB consensus sequence is
shown in bold face: 5P-CTGCCCTGGGTTTCCCCTTGAAGGGA-
TTTCCCTCCGCC-3P.
2.7. Statistical analysis
All values are expressed as meanRS.D. Signi¢cance of di¡erences
between group means was assessed by Student’s unpaired t-test or
one-way ANOVA followed by Tukey^Kramer multiple comparison
test. P values less than 0.05 were considered to indicate statistical
signi¢cance.
3. Results
First, we examined the expression of the AR gene in
HAEC. Using the RT-PCR method, ampli¢ed products with
the expected size corresponding to the transcripts were de-
tected (Fig. 1). Cloning and sequence analysis of the PCR
products demonstrated that these bands had the known se-
quence of the human AR mRNA (data not shown). The tran-
script of the 5K-R1 gene was obtained from HAEC after 35
cycles of PCR were performed. We failed to detect the prod-
ucts of 5K-R2 and aromatase mRNAs in HAEC, even after 35
cycles of PCR.
Next, 5K-R activity was measured by a radiometric conver-
sion assay. Under these incubation conditions, there was no
signi¢cant 5K-R activity in these cells (10.2 R 2.0%) compared
with blank assays (8.6 R 2.1%) (n=6 in each group, P=0.21).
HAEC were tested for their ability to bind to [3H]T or
[3H]5KDHT. The speci¢c binding of both ligands was satura-
ble (Fig. 2). Scatchard analyses of the binding data revealed a
single class of binding sites for T with an apparent Kd of
2.01R 0.42 nM and an apparent Bmax of 44.8R 8.5 fmol/mg
protein, and for 5KDHT with a Kd of 1.92R 0.55 nM and a
Bmax of 51.8R 10.5 fmol/mg protein.
To examine the e¡ect of androgens on TNF-K-induced
VCAM-1 mRNA accumulation, Northern blot analysis was
performed. Since T and 5KDHT had similar Bmax and Kd
values and no signi¢cant 5K-R activity was observed in
HAEC, we tested the e¡ect of T in the following experiments.
As shown in Fig. 3, TNF-K increased the VCAM-1 mRNA
level. Treatment with T inhibited the VCAM-1 expression in a
concentration-dependent manner, with a maximal decrease
(49R 16%) at 1 WM. The inhibition of VCAM-1 expression
was completely blocked by the concomitant administration
of a steroidal AR blocker, cyproterone acetate (CPA).
To determine whether T regulates VCAM-1 expression by
inhibiting NF-UB activation, we performed EMSA with nu-
clear extracts and cytoplasmic extracts from HAEC. EMSA
with the oligonucleotide probe containing NF-UB binding
sites in the human VCAM-1 gene promoter showed that
TNF-K enhanced two of the gel-retarded bands (Fig. 4A,
lanes 1 and 3). Speci¢city of the complexes was demonstrated
with antibodies against NF-UB subunit Rel A (p65) and p50,
which supershifted the complexes, and by competition with an
excess of unlabeled oligonucleotide (Fig. 4A, lanes 6^9). T
markedly decreased the intensity of the shifted bands pro-
duced by nuclear extracts treated with TNF-K, and the de-
crease of NF-UB activation was partially abolished by the
presence of AR blocker (Fig. 4A, lanes 3^5). Cytoplasmic
extracts from the same cells showed little di¡erence (Fig.
Fig. 1. Detection of AR, 5K-R1, 5K-R2 and aromatase mRNAs in
HAEC by RT-PCR. Total RNAs (1 Wg) were ampli¢ed by RT-PCR
as described. The prostate total RNA (Sigma, St. Louis, MO, USA)
was used as a positive control. Each experiment was repeated three
times, and the data shown are representative of three independent
results.
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4B, lanes 3^5). T alone did not exhibit any signi¢cant di¡er-
ences in NF-UB activation (Fig. 4A, lanes 1 and 2).
4. Discussion
Leukocyte adhesion to the endothelium via adhesion mole-
cules is one of the earliest events in atherosclerosis. It has been
suggested that VCAM-1 plays a very important role in the
recruitment of leukocytes into the vascular wall [20,21]. Re-
cent evidence indicates that the promoter region of the
VCAM-1 gene contains NF-UB binding sites which are essen-
tial for the expression of the gene [9]. NF-UB, a transcrip-
tional activator factor, is present in the cytoplasm of unstim-
ulated cells in an inactive form, complexed to the inhibitory
protein IUB. Cellular activation by cytokines such as TNF-K
induces phosphorylation and degradation of IUB, with subse-
quent liberation and translocation of NF-UB to the nucleus
[8]. NF-UB then binds to speci¢c DNA sequences in the 5P-
£anking region of VCAM-1 gene [22].
In the present study, we demonstrated that T inhibits TNF-
K-induced VCAM-1 expression and NF-UB activation
through an interaction with AR in HAEC. Since EMSA
with cytoplasmic extracts showed little di¡erence in the NF-
UB binding, and T alone did not exert signi¢cant e¡ects, the
mechanism by which T inhibits TNF-K-induced VCAM-1 ex-
pression is probably mediated by inhibition of the TNF-K-
induced NF-UB nuclear translocation. Because there is no
evidence that androgen response elements exist on the
Fig. 2. Saturation curves and Scatchard analyses of [3H]T (A) and
[3H]5KDHT (B) binding to HAEC. Each point represents the mean
of triplicate assays. Non-speci¢c binding was less than 10% of total
binding in all assays.
Fig. 3. E¡ect of T on TNF-K-induced VCAM-1 expression in
HAEC. Con£uent cells were incubated with test compounds or ve-
hicle (0.1% ethanol) for 24 h in phenol red-free and serum-free me-
dium, and thereafter were stimulated with 20 ng/ml TNF-K for 4 h.
Experiments were repeated three times with equal results. The indi-
vidual result was obtained by the calculation of the intensity of the
VCAM-1 band divided by that of the GAPDH band, and related to
the mean of control group. *P6 0.05 compared with control;
#P6 0.05 compared with cells cultured with 20 ng/ml TNF-K and
100 nM of T in the absence of CPA, a steroidal antiandrogen.
Fig. 4. E¡ect of T on DNA binding activity of NF-UB. HAEC were
treated as described in Fig. 3. EMSA with use of the oligonucleo-
tide probe speci¢c for the NF-UB binding of human VCAM-1 gene
promoter was performed on nuclear extracts (A) and cytoplasmic
extracts (B) with no reagents (lanes 1^5), 50-fold excess of unlabeled
NF-UB oligonucleotide (lane 6), 50-fold excess of unlabeled stimula-
tory protein-1 (SP-1) oligonucleotide (lane 7), anti-p65 antibody
(anti-p65 Ab, lane 8) and anti-p50 antibody (anti-p50 Ab, lane 9).
Arrowheads indicate NF-UB binding to DNA. Large and small ar-
rows indicate supershifted bands in lanes 8 and 9, respectively. Data
shown are representative of three separate experiments.
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VCAM-1 gene promoter, it is unlikely that T-bound AR di-
rectly interacts with the 5P-£anking region of the VCAM-1
gene. Simoncini et al. demonstrated that 17L-estradiol de-
creased VCAM-1 gene expression through the inhibition of
the NF-UB nuclear translocation, with the inhibition associ-
ated with decreased IUB kinase activity [23].
Our results provide evidence for the presence of AR by RT-
PCR and receptor binding methods. In the binding study, T
and 5KDHT had similar Bmax and Kd values. Wilson et al.
demonstrated that AR has essentially identical capabilities to
bind T and 5KDHT in rat testis, epididymis and prostate [24].
McCrohon et al. reported that 5KDHT increased human
monocyte adhesion to vascular endothelium, at least in part
through an AR-mediated e¡ect on endothelial expression of
VCAM-1 [25]. In many androgen target tissues, it has been
suggested that 5KDHT is the active form of androgen and T is
reduced to 5KDHT by the enzyme 5K-R before binding to
AR. However, abundant physiologic and genetic data demon-
strate that T and 5KDHT are not biologically equivalent.
Conformational changes that occur as a result of the binding
of di¡erent ligands form the structural basis for the recruit-
ment of di¡erent cofactors to nuclear receptors. These
changes may contribute to the diversity of androgen action.
Powers and Florini found that T, not 5KDHT, stimulates
mitotic activity in a myoblast culture system and this result
suggests a possibility that T a¡ects muscles by direct interac-
tion with the AR [26]. This is supported by the ¢nding that
5K-R activity in muscle tissue was lower than that in accessory
sex organs [27]. Although we detected the small amount of
mRNA of 5K-R1 which displays a low a⁄nity for T, no sig-
ni¢cant 5K-R activity was observed in the present study.
Clinical manifestations of atherosclerosis, such as coronary
heart disease, occur at a higher frequency in the western
world. It has been postulated that male sex along with other
factors accelerates the progression rate of the atherosclerotic
process. However, available data do not support the role of
androgens in atherogenesis. Alexandersen et al. have sug-
gested an anti-atherogenic e¡ect of T in animal studies [28].
Further studies of the possible bene¢ts of androgens in the
prevention of atherosclerosis are needed. Nevertheless, the
present ¢ndings provide novel insight into the consideration
of androgen replacement therapy and understanding of the
pathogenesis of atherosclerosis.
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